276 related articles for article (PubMed ID: 30894629)
1. A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma.
Stringer BW; Day BW; D'Souza RCJ; Jamieson PR; Ensbey KS; Bruce ZC; Lim YC; Goasdoué K; Offenhäuser C; Akgül S; Allan S; Robertson T; Lucas P; Tollesson G; Campbell S; Winter C; Do H; Dobrovic A; Inglis PL; Jeffree RL; Johns TG; Boyd AW
Sci Rep; 2019 Mar; 9(1):4902. PubMed ID: 30894629
[TBL] [Abstract][Full Text] [Related]
2. Generation of Glioblastoma Patient-Derived Intracranial Xenografts for Preclinical Studies.
Kerstetter-Fogle AE; Harris PLR; Brady-Kalnay SM; Sloan AE
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698368
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
[TBL] [Abstract][Full Text] [Related]
4. Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma.
Stringer BW; Bunt J; Day BW; Barry G; Jamieson PR; Ensbey KS; Bruce ZC; Goasdoué K; Vidal H; Charmsaz S; Smith FM; Cooper LT; Piper M; Boyd AW; Richards LJ
Oncotarget; 2016 May; 7(20):29306-20. PubMed ID: 27083054
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
[TBL] [Abstract][Full Text] [Related]
6. High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma.
Yu KK; Taylor JT; Pathmanaban ON; Youshani AS; Beyit D; Dutko-Gwozdz J; Benson R; Griffiths G; Peers I; Cueppens P; Telfer BA; Williams KJ; McBain C; Kamaly-Asl ID; Bigger BW
PLoS One; 2018; 13(3):e0193694. PubMed ID: 29499065
[TBL] [Abstract][Full Text] [Related]
7. Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44.
Rimkus TK; Carpenter RL; Sirkisoon S; Zhu D; Pasche BC; Chan MD; Lesser GJ; Tatter SB; Watabe K; Debinski W; Lo HW
Cancer Res; 2018 May; 78(10):2589-2600. PubMed ID: 29463580
[TBL] [Abstract][Full Text] [Related]
8. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.
Teng J; da Hora CC; Kantar RS; Nakano I; Wakimoto H; Batchelor TT; Chiocca EA; Badr CE; Tannous BA
Neuro Oncol; 2017 Jun; 19(6):820-832. PubMed ID: 28062830
[TBL] [Abstract][Full Text] [Related]
9. A recombinant lentiviral PDGF-driven mouse model of proneural glioblastoma.
Rahme GJ; Luikart BW; Cheng C; Israel MA
Neuro Oncol; 2018 Feb; 20(3):332-342. PubMed ID: 29016807
[TBL] [Abstract][Full Text] [Related]
10. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment.
Tejero R; Huang Y; Katsyv I; Kluge M; Lin JY; Tome-Garcia J; Daviaud N; Wang Y; Zhang B; Tsankova NM; Friedel CC; Zou H; Friedel RH
EBioMedicine; 2019 Apr; 42():252-269. PubMed ID: 30952620
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma Model Using Human Cerebral Organoids.
Ogawa J; Pao GM; Shokhirev MN; Verma IM
Cell Rep; 2018 Apr; 23(4):1220-1229. PubMed ID: 29694897
[TBL] [Abstract][Full Text] [Related]
12. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
13. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
14. Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.
Olmez I; Love S; Xiao A; Manigat L; Randolph P; McKenna BD; Neal BP; Boroda S; Li M; Brenneman B; Abounader R; Floyd D; Lee J; Nakano I; Godlewski J; Bronisz A; Sulman EP; Mayo M; Gioeli D; Weber M; Harris TE; Purow B
Neuro Oncol; 2018 Jan; 20(2):192-202. PubMed ID: 29048560
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models.
Jandial R; Neman J; Lim PP; Tamae D; Kowolik CM; Wuenschell GE; Shuck SC; Ciminera AK; De Jesus LR; Ouyang C; Chen MY; Termini J
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385725
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments.
Achyut BR; Shankar A; Iskander AS; Ara R; Knight RA; Scicli AG; Arbab AS
Cancer Biol Ther; 2016; 17(3):280-90. PubMed ID: 26797476
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma.
Luedi MM; Singh SK; Mosley JC; Hassan ISA; Hatami M; Gumin J; Andereggen L; Sulman EP; Lang FF; Stueber F; Fuller GN; Colen RR; Zinn PO
J Neurosurg; 2018 Dec; 129(6):1446-1455. PubMed ID: 29328002
[TBL] [Abstract][Full Text] [Related]
18. Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes.
Cusulin C; Chesnelong C; Bose P; Bilenky M; Kopciuk K; Chan JA; Cairncross JG; Jones SJ; Marra MA; Luchman HA; Weiss S
Stem Cell Reports; 2015 Jul; 5(1):1-9. PubMed ID: 26095605
[TBL] [Abstract][Full Text] [Related]
19. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
Xia S; Lal B; Tung B; Wang S; Goodwin CR; Laterra J
Neuro Oncol; 2016 Apr; 18(4):507-17. PubMed ID: 26320116
[TBL] [Abstract][Full Text] [Related]
20. Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.
Kratzsch T; Kuhn SA; Joedicke A; Hanisch UK; Vajkoczy P; Hoffmann J; Fichtner I
J Cancer Res Clin Oncol; 2018 May; 144(5):809-819. PubMed ID: 29427211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
